Driven by pressure to conduct trials more quickly and at reduced
cost, biopharmaceutical companies are focusing on recruitment as a
critical area. The Enrollment Insights Study provides in-depth
analysis of enrollment performance and practices. It not only
reports on essential performance indicators, but on the ways
companies execute strategy. Gain insight into why some companies
achieve better performance than others, and how your company can
accelerate its patient recruitment.
Among the performance indicators to be assessed are screen failure rates, drop-out rates, randomization rates, recruitment cycle time, and site initiation cycle times. The study undertakes a detailed review of recruitment, including how performance varies by disease, and couples that performance with region/country. Understand, too, the level of recruitment taking place outside North America and Western Europe and whether entry into emerging markets has had significant effect on a given company’s ability to accelerate recruitment. Explore relationships between the overall trial and its sites and how these relationships alter a trial’s success.
Use results from this study to assess enrollment performance and gain insight into the key factors and types of decisions that most influence any given trial’s success.